A National Survey: Desire of Dermatology Residents to Train in Cosmetic Dermatology and Its Association With Learning Medical Dermatology

The main challenge for training in cosmetic dermatology is the difference in the attitudes of residency programs and residents about the necessity and amount of education during the residency period. A national online survey conducted between September 6th and November 21st, 2017. Residents, members of the Iranian Board of Dermatology, faculty members and program directors (PDs) were asked to participate in the survey.174 participants from 12 residency programs participated in this study and the response rate of residents, professors, and Dermatology Board Directory Members (Boardmans) and PDs was 89.8%, 61.7%, and 81.8%, respectively. Residents declared greater tendency towards practicing medical dermatology (mean score, 5.165±0.8335) over the five years after graduation than that of was perceived by professors (4.043±1.2988), and Boardmans and PDs (4.059±1.0290) (P˂0.001). The first residents’ priority was practicing in medical dermatology (5.165±0.8335) during 5-years after graduation. However, professors (5.261±0.8282) and Boardmans and PDs (5.176±0.7276) predicted residents' first priority would be practicing cosmetic dermatology (P˂0.001). Forty one (60.3%) of the professors, Boardmans, and PDs agreed or strongly agreed that residents’ desire to learn more about cosmetic procedures resulted in their decreased interest in learning medical procedures (P=0.18). Medical dermatology is still clearly the basis for training in residency programs,and even for residents who have a high tendency to practice cosmetic dermatology, there is a strong tendency to work in the field of medical dermatology as well

Non-alcoholic fatty liver disease (NAFLD) and obesity in inflammatory bowel disease (IBD) patients in Gorgan

Background: According to the significance of extraintestinal symptoms in inflammatory bowel disease (IBD) patients and their connection with obesity, we aimed to investigate the prevalence of fatty liver in IBD patients of Sayyad Shirazi Hospital in Gorgan, Iran, in relation to obesity, anthropometric indicators and body image in these patients. Methods: Forty patients with IBD were recruited from all registered patients at the Golestan Research Center of Gastroenterology and Hepatology, following the specified inclusion and exclusion criteria. After obtaining written informed consent and filling in the questionnaire, the demographic and anthropometric indicators, and variables related to the disease were measured. The liver sonography was performed on all patients and graded by an expert radiologist. Data were analyzed using SPSS Version 16.0 statistical software at the significance level of 0.05. Results: We showed no significant difference between the distribution of demographic and anthropometric indicators in different groups of IBD patients. However, we demonstrated that the inappropriate values of HDL (0.004) and high values of LDL (0.015) were associated with fatty liver in IBD patients. Our findings also showed that NAFLD was significantly associated with overweight and obesity among IBD patients (P = 0.003). Conclusion: Our findings showed the epidemiological burden of NAFLD in IBD patients. Since fatty liver was associated with obesity, it is recommended that IBD patients be screened for risk factors associated with NAFLD to prevent liver disease

Rosuvastatin Intervention in Patients with Chronic Hepatitis B (CHB) Expands CD14+ CD16− Classical Monocytes via Aryl Hydrocarbon Receptor (AHR)

Chronic hepatitis B (CHB) poses treatment challenges, with treatment response and disease outcome often determined by the immune response, particularly mononuclear phagocytes. Monocytes can differentiate into various subpopulations influenced by AHR. Statins, known for inflammation modulation, may impact monocyte function via AHR activation. This study explored rosuvastatin (RSV)’s effects on monocyte subtypes, inflammatory markers, and AHR in CHB patients. Fifteen CHB patients were randomly assigned to receive either 20 mg RSV or a placebo daily for three months. Flow cytometry assessed CD14+ CD16− (classical), CD14+ CD16+ (intermediate), and CD14dim CD16+ (patrolling) monocyte subtypes, along with AHR levels in each subset. ELISA quantified cytokines IL-6, IFN-γ, IL-12, IL-10, TNF-α, TGF-β, and IL-1β. RSV expanded CD14+ CD16− classical and reduced CD14+ CD16+ intermediate monocytes in CHB patients while increasing AHR+ cell percentages in all subsets. RSV treatment upregulated key AHR target genes (Cyp1a1, Cyp1b1, and ARNT), indicating robust AHR signaling activation. It also reduced pro-inflammatory cytokine levels (IL-6, IFNγ, IL-12, TNF-α) and elevated anti-inflammatory cytokines (IL-10, TGF-β). Thus, RSV may modulate the immune response by altering monocyte subtypes in CHB patients via AHR activation